Patents by Inventor Bernard Tonnerre

Bernard Tonnerre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Indolizine derivatives, method for preparing same, and therapeutic compositions comprising same
    Patent number: 7799799
    Abstract: The present invention is directed to compounds of formula (I): described as novel indolizine derivatives and to a method for their preparation along with pharmaceutical compositions thereof whose substituents are as described in the specification.
    Type: Grant
    Filed: May 8, 2008
    Date of Patent: September 21, 2010
    Assignee: Sanofi-Aventis
    Inventors: Patrick Gautier, David Marchionni, Alain Roccon, Bernard Tonnerre, Jean Wagnon
  • N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS
    Publication number: 20100093668
    Abstract: The disclosure relates to a compound of formula (I): wherein R, R1, R2, R3, R4, R5, R6 and Z are as defined in the specification, to compositions containing them, to processes for preparing them, and to their use in the treatment or prevention of conditions capable of being modulated by the inhibition of the activity of protein kinases.
    Type: Application
    Filed: July 1, 2009
    Publication date: April 15, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Didier BABIN, Monsif BOUABOULA, Pierre CASELLAS, Maria MENDEZ-PEREZ, Serge MIGNANI, Jean-Flaubert NGUEFACK, Jacob-Alsboek OLSEN, Bernard TONNERRE, Jean WAGNON
  • NOVEL PHENYL(4-PHENYLPYRIMIDIN-2-YL)AMINE DERIVATIVES, THEIR PREPARATION, AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS
    Publication number: 20100069417
    Abstract: The disclosure relates to a compound of formula (I): wherein R, R2, R3, R4, R5, Z, W and D are as defined in the specification, to compositions containing them, to processes for preparing them, and to their use in the treatment or prevention of conditions capable of being modulated by the inhibition of the activity of protein kinases.
    Type: Application
    Filed: July 1, 2009
    Publication date: March 18, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Monsif BOUABOULA, Pierre CASELLAS, Sherri DUDAL, Regine FLOUTARD, Maria MENDEZ-PEREZ, Jean-Flaubert NGUEFACK, Jacob-Alsboek OLSEN, Bernard TONNERRE, Jean WAGNON
  • NEW 2,4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS
    Publication number: 20100035907
    Abstract: The disclosure relates to a compound of formula (I): wherein R1, R2, R3, R4, R5, A and Y are as defined in the specification, to compositions containing them, to processes for preparing them, and to their use in the treatment or prevention of conditions capable of being modulated by the inhibition of the activity of protein kinases.
    Type: Application
    Filed: July 1, 2009
    Publication date: February 11, 2010
    Applicant: Sanofi-aventis
    Inventors: Monsif BOUABOULA, Michael BOSCH, Pierre CASELLAS, Jean-Flaubert Nguefack, Bernard Tonnerre, Jean Wagnon
  • Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
    Patent number: 7468368
    Abstract: The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; p is 1 or 2; R1 represents a halogen atom; a trifluoromethyl radical; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethoxy radical; R2 represents a hydrogen atom or a halogen atom; R3 represents a hydrogen atom; a group —OR5; a group —CH2OR5; a group —NR6R7; a group —NR8COR9; a group —NR8CONR10R11; a group —CH2NR12R13; a group —CH2NR8CONR14R15; a (C1-C4)alkoxycarbonyl; a group —CONR16R17; or else R3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R4 represents an aromatic group selected from: the said aromatic groups being unsubstituted or being mono- or disubstituted by a substituent selected independently from a halogen atom; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethyl radical; Preparation process and therapeutic application.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: December 23, 2008
    Assignee: Sanofi Aventis
    Inventors: Françoise Bono, Michaël Bosch, Victor Dos Santos, Jean-Marc Herbert, Dino Nisato, Bernard Tonnerre, Jean Wagnon
  • NOVEL INDOLIZINE DERIVATIVES, METHOD FOR PREPARING SAME, AND THERAPEUTIC COMPOSITIONS COMPRISING SAME
    Publication number: 20080287485
    Abstract: The present invention is directed to compounds of formula (I): described as novel indolizine derivatives and to a method for their preparation along with pharmaceutical compositions thereof whose substituents are as described in the specification.
    Type: Application
    Filed: May 8, 2008
    Publication date: November 20, 2008
    Applicant: SANOFI-AVENTIS
    Inventors: Patrick GAUTIER, David Marchionni, Alain Roccon, Bernard Tonnerre, Jean Wagnon
  • Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors
    Publication number: 20080269170
    Abstract: The disclosure relates to compounds of formula (I): wherein R1-R5, A and Y are as defined in the disclosure, to compositions comprising said compounds, and to processes for making and methods of using the same.
    Type: Application
    Filed: January 9, 2008
    Publication date: October 30, 2008
    Applicant: sanofi-aventis
    Inventors: Michael Bosch, Monsif Bouaboula, Pierre Casellas, Samir Jegham, Serge Mignani, Jean-Flaubert Nguefack, Jacob-Alsboek Olsen, Bernard Tonnerre, Jean Wagnon
  • 1,3-dihydro-2-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them
    Patent number: 7297692
    Abstract: The invention relates to compounds of formula: as well as the possible salts thereof with mineral or organic acids, and the solvates and/or hydrates thereof, which have affinity for and selectivity towards the V1b receptors or towards both the V1b and V1a receptors of arginine-vasopressin. The invention also relates to the process for preparing them, to the intermediate compounds of formula (II) that are useful for preparing them, to pharmaceutical compositions containing them and to their use for the preparation of medicinal products.
    Type: Grant
    Filed: August 3, 2006
    Date of Patent: November 20, 2007
    Assignee: Sanofi-Aventis
    Inventors: Richard Roux, Claudine Serradeil-Le Gal, Bernard Tonnerre, Jean Wagnon
  • Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
    Patent number: 7294628
    Abstract: The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; R1 represents a halogen atom; a trifluoromethyl radical; a (C1-C4) alkyl; a (C1-C4)alkoxy; a trifluoromethoxy radical; R2 represents a hydrogen atom or a halogen atom; R3 represents a hydrogen atom; a group —OR5; a group —CH2OR5; a group —NR6R7; a group —NR8COR9; a group —NR8CONR10R11; a group —CH2NR12R13; a group —CH2NR8CONR14R15; a (C1-C4)alkoxycarbonyl; a group —CONR16R17; or else R3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R4 represents the aromatic group 1,3-thiazol-2-yl of formula: Preparation process and therapeutic application.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: November 13, 2007
    Assignee: Sanofi-Aventis
    Inventors: Françoise Bono, Michaël Bosch, Victor Dos Santos, Jean-Marc Herbert, Dino Nisato, Bernard Tonnerre, Jean Wagnon
  • NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    Publication number: 20070004703
    Abstract: The invention relates to compounds of formula: as well as the possible salts thereof with mineral or organic acids, and the solvates and/or hydrates thereof, which have affinity for and selectivity towards the V1b receptors or towards both the V1b and V1a receptors of arginine-vasopressin. The invention also relates to the process for preparing them, to the intermediate compounds of formula (II) that are useful for preparing them, to pharmaceutical compositions containing them and to their use for the preparation of medicinal products.
    Type: Application
    Filed: August 3, 2006
    Publication date: January 4, 2007
    Applicant: SANOFI-AVENTIS
    Inventors: Richard Roux, Claudine Serradeil-Le Gal, Bernard Tonnerre, Jean Wagnon
  • 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them
    Patent number: 7129240
    Abstract: The invention relates to compounds of formula: as well as the possible salts thereof with mineral or organic acids, and the solvates and/or hydrates thereof, which have affinity for and selectivity towards the V1b receptors or towards both the V1b and V1a receptors of arginine-vasopressin. The invention also relates to the process for preparing them, to the intermediate compounds of formula (II) that are useful for preparing them, to pharmaceutical compositions containing them and to their use for the preparation of medicinal products.
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: October 31, 2006
    Assignee: Sanofi-Aventis
    Inventors: Richard Roux, Claudine Serradeil-le Gal, Bernard Tonnerre, Jean Wagnon
  • Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
    Patent number: 7119086
    Abstract: The invention relates to compounds of formula: and also to the salts thereof with mineral or organic acids, and the solvates and/or hydrates thereof, with affinity for and selectivity towards the arginine-vasopressin V1b receptors and/or for the ocytocin receptors and, furthermore, for certain compounds, affinity for the V1a receptors. The invention also relates to the process for preparing them, to the intermediate compounds of formula (IV) that are useful for preparing them, to pharmaceutical compositions containing them and to their use for preparing medicinal products.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: October 10, 2006
    Assignee: Sanofi-Aventis
    Inventors: Alain Di Malta, Georges Garcia, Richard Roux, Bruno Schoentjes, Claudine Serradeil-Le Gal, Bernard Tonnerre, Jean Wagnon
  • Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
    Publication number: 20060167007
    Abstract: The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; R1 represents a halogen atom; a trifluoromethyl radical; a (C1-C4) alkyl; a (C1-C4)alkoxy; a trifluoromethoxy radical; R2 represents a hydrogen atom or a halogen atom; R3 represents a hydrogen atom; a group —OR5; a group —CH2OR5; a group —NR6R7; a group —NR8COR9; a group —NR8CONR10R11; a group —CH2NR12R13; a group —CH2NR8CONR14R15; a (C1-C4)alkoxycarbonyl; a group —CONR16R17; or else R3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R4 represents the aromatic group 1,3-thiazol-2-yl of formula: Preparation process and therapeutic application.
    Type: Application
    Filed: June 5, 2003
    Publication date: July 27, 2006
    Applicant: sanofi-aventis
    Inventors: Francoise Bono, Michael Bosch, Victor Dos Santos, Jean-Marc Herbert, Dino Nisato, Bernard Tonnerre, Jean Wagnon
  • Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
    Publication number: 20050176722
    Abstract: The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; p is 1 or 2; R1 represents a halogen atom; a trifluoromethyl radical; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethoxy radical; R2 represents a hydrogen atom or a halogen atom; R3 represents a hydrogen atom; a group —OR5; a group —CH2OR5; a group —NR6R7; a group —NR8COR9; a group —NR8CONR10R11; a group —CH2NR12R13; a group —CH2NR8CONR14R15; a (C1-C4)alkoxycarbonyl; a group —CONR16R17; or else R3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R4 represents an aromatic group selected from: the said aromatic groups being unsubstituted or being mono- or disubstituted by a substituent selected independently from a halogen atom; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethyl radical; Preparation process and therapeutic application.
    Type: Application
    Filed: June 5, 2003
    Publication date: August 11, 2005
    Applicant: sanofi-aventis
    Inventors: Francoise Bono, Michael Bosch, Victor Dos Santos, Jean-Marc Herbert, Dino Nisato, Bernard Tonnerre, Jean Wagnon
  • Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them
    Publication number: 20040209938
    Abstract: The invention relates to compounds of formula: 1
    Type: Application
    Filed: April 29, 2004
    Publication date: October 21, 2004
    Inventors: Richard Roux, Claudine Serradeil-Le Gal, Bernard Tonnerre, Jean Wagnon
  • Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
    Publication number: 20040180878
    Abstract: The invention relates to compounds of formula: 1
    Type: Application
    Filed: January 16, 2004
    Publication date: September 16, 2004
    Inventors: Alain Di Malta, Georges Garcia, Richard Roux, Bruno Schoentjes, Claudine Serradeil-Le Gal, Bernard Tonnerre, Jean Wagnon
  • 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for V1b and V1a arginine-vasopressin receptors
    Patent number: 6730695
    Abstract: The invention relates to compounds of formula: as well as the possible salts thereof with mineral or organic acids, and the solvates and/or hydrates thereof, which have affinity for and selectivity towards the V1b receptors or towards both the V1b and V1a receptors of arginine-vasopressin. The invention also relates to the process for preparing them, to the intermediate compounds of formula (II) that are useful for preparing them, to pharmaceutical compositions containing them and to their use for the preparation of medicinal products.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: May 4, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Richard Roux, Claudine Serradeil-Le Gal, Bernard Tonnerre, Jean Wagnon
  • 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
    Patent number: 6596732
    Abstract: The invention relates to compounds of formula: and their solvates and/or hydrates exhibiting an affinity and a selectivity for arginine-vasopressin V1b receptors or for both V1b and V1a receptors.
    Type: Grant
    Filed: August 12, 2002
    Date of Patent: July 22, 2003
    Assignee: Sanofi-Synthelabo
    Inventors: Claudine Serradeil-Le Gal, Bernard Tonnerre, Jean Wagnon
  • Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors
    Publication number: 20030114683
    Abstract: The invention relates to compounds of formula: 1
    Type: Application
    Filed: July 24, 2002
    Publication date: June 19, 2003
    Inventors: Richard Roux, Claudine Serradeil-Le Gal, Bernard Tonnerre, Jean Wagnon
  • Indol-2-one derivatives
    Patent number: 5773612
    Abstract: A compound of formula II' ##STR1## in whichR.sub.I is an ethoxy group or a chlorine atom;R.sub.II is hydrogen, a chlorine atom or a methyl group;R.sub.III is a chlorophenyl group or a methoxyphenyl group;R.sub.IV is an amino group, a group NR.sub.9 R.sub.10 or NR.sub.9 R.sub.XI, or a piperazin-1-yl radical substituted in the 4-position by a (C.sub.2 -C.sub.10)alkylene group substituted by an amino group which is free or carries a protective group;R.sub.10 is (CH.sub.2).sub.p R.sub.35 or a (C.sub.2 -C.sub.10)alkylene group substituted by R.sub.21 ;R.sub.XI is a (C.sub.1 -C.sub.12)alkyl group or a group .omega.-R.sub.32 R.sub.33 N(C.sub.1 -C.sub.4)-alkylcarbonyl; andR.sub.21 is R.sub.36 ; a group OR.sub.37 ; a group NR.sub.32 R.sub.33 ; a cyano group; a group S(C.sub.1 -C.sub.7)alkyl; a group SO(C.sub.1 -C.sub.7)alkyl; or a group SO.sub.2 (C.sub.1 -C.sub.7)alkyl;R.sub.35 is a piperid-4-yl group which is unsubstituted or substituted in the 1-position by a (C.sub.1 -C.sub.7)alkoxycarbonyl group or by a (C.sub.
    Type: Grant
    Filed: April 30, 1996
    Date of Patent: June 30, 1998
    Assignee: Sanofi
    Inventors: Jean Wagnon, Bernard Tonnerre, Alain Di Malta, Richard Roux, Marie-Sophie Amiel, Claudine Serradeil-Legal